UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The role of bosutinib in the treatment of chronic myeloid leukemia

Future oncology (London, England), 2020-01, Vol.16 (2), p.4395-4408

2020

Volltextzugriff (PDF)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Leukemia, 2021-05, Vol.35 (5), p.1344-1355

2021

Volltextzugriff (PDF)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Journal of clinical oncology, 2018-01, Vol.36 (3), p.231-237

2018

Volltextzugriff (PDF)

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Journal of hematology and oncology, 2021-02, Vol.14 (1), p.35-11, Article 35

2021

Volltextzugriff (PDF)

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

British journal of haematology, 2020-06, Vol.189 (5), p.888-903

2020

Volltextzugriff (PDF)

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Leukemia, 2022-07, Vol.36 (7), p.1825-1833

2022

Volltextzugriff (PDF)

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

The New England journal of medicine, 2024-09, Vol.391 (10), p.885-898

2024

Volltextzugriff (PDF)

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Haematologica (Roma), 2016-09, Vol.101 (9), p.1065-1073

2016

Volltextzugriff (PDF)

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

American journal of hematology, 2015-10, Vol.90 (10), p.910-914

2015

Volltextzugriff (PDF)

Single-cell analysis based dissection of clonality in myelofibrosis

Nature communications, 2020-01, Vol.11 (1), p.73-73, Article 73

2020

Volltextzugriff (PDF)

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

Haematologica (Roma), 2019-12, Vol.104 (12), p.e551-e554

2019

Volltextzugriff (PDF)

HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells

Scientific reports, 2019-10, Vol.9 (1), p.14029-13, Article 14029

2019

Volltextzugriff (PDF)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia

American journal of hematology, 2022-08, Vol.97 (8), p.E296-E298

2022

Volltextzugriff (PDF)

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Haematologica (Roma), 2014-07, Vol.99 (7), p.1204-1211

2014

Volltextzugriff (PDF)

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome

European journal of haematology, 2015-12, Vol.95 (6), p.498-506

2015

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport

The journal of clinical endocrinology and metabolism, 2012-01, Vol.97 (1), p.E100-E105

2012

Volltextzugriff (PDF)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Journal of cancer research and clinical oncology, 2018-05, Vol.144 (5), p.945-954

2018

Volltextzugriff (PDF)

Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort

Frontiers in oncology, 2021-11, Vol.11, p.772809-772809

2021

Volltextzugriff (PDF)

Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Frontiers in oncology, 2024-02, Vol.14, p.1345050-1345050

2024

Volltextzugriff (PDF)

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Frontiers in oncology, 2023-01, Vol.12, p.1056786-1056786

2023

Volltextzugriff (PDF)

1 – 25 von 3.540

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.435)
Mit Volltextzugriff
(3.192)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(954)
Ebook Central Perpetual and DDA
(660)
eBooks on EBSCOhost
(559)
Ingenta
(539)
Publisher website
(304)
MEDLINE
(297)
De Gruyter eBooks
(292)
IngentaConnect Journals
(287)
Journals@Ovid Complete
(244)
JSTOR
(196)
Elsevier ScienceDirect Journals Complete
(189)
Wiley-Blackwell Journals
(100)
SpringerLink Journals - AutoHoldings
(84)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(83)
Wiley Online Library Full Collection 2018
(82)
Business Source Ultimate
(72)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(66)
Nomos eLibrary
(57)
Nature
(50)
De Gruyter Open Access Books
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(158)
Shs Web Of Conferences
(158)
Forum Médical Suisse
(54)
Revue Française De Gestion
(36)
Verfassung Und Recht In Übersee
(28)
Revue Philosophique De Louvain
(23)
Clinical Lymphoma, Myeloma And Leukemia
(22)
Journal Of Clinical Oncology
(14)
Bulletin Des Médecins Suisses
(13)
Therapie
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The role of bosutinib in the treatment of chronic myeloid leukemia

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

Single-cell analysis based dissection of clonality in myelofibrosis

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome

Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Survey of Long-Term Experiences of Sperm Cryopreservation in Oncological and Non-Oncological Patients: Usage and Reproductive Outcomes of a Large Monocentric Cohort

Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Suchergebnisse filtern